588. Ceftolozane/Tazobactam Susceptibility of Carbapenem-Resistant Pseudomonas aeruginosa and Carbapenem-Resistant Enterobacterales Isolates in a Tertiary Hospital in Korea

Abstract

Abstract Background Carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are significant nosocomial pathogens that pose significant challenges in treatment due to their multidrug-resistant nature. Ceftolozane/tazobactam (C/T) is a novel antimicrobial agent that has shown promising activity against these pathogens. However, there is limited data available on its susceptibility against these resistant isolates in Korea. The aim of this study is to determine the in vitro susceptibility of C/T against CRE and CRPA isolates in a tertiary hospital in Korea. Methods Blood isolates of CRE and CRPA were collected from a tertiary hospital between September 2017 and September 2022. A carbapenemase test was performed using NG test CARBA-5. For non-carbapenemase-producing CRE and CRPA, the minimum inhibitory concentration of C/T was determined using the Etest and interpreted according to the CLSI breakpoints. Results A total of 120 blood isolates, including 55 CRE and 65 CRPA, were analyzed. Carbapenemase-producing isolates were found in 60.0% of CRE and 27.7% of CRPA samples. Among the CRE isolates, KPC (50.9%), NDM (7.3%), and OXA-48-like (1.8%) carbapenemases were identified, while NDM (21.5%), IMP (3.1%), and VIM (3.1%) were found in CRPA isolates. For the non-carbapenemase-producing isolates, the susceptible, intermediate, and resistant rates to C/T were 9.1%, 7.3%, and 23.6%, respectively, for CRE, and 67.7%, 3.1%, and 1.5%, respectively, for CRPA. Conclusion This study provides important information on the in vitro susceptibility of C/T against CRE and CRPA isolates in Korea. The findings will help guide empirical antibiotic therapy and improve patient outcomes. Further studies are needed to evaluate the clinical efficacy of C/T against these resistant pathogens in Korea. Disclosures All Authors: No reported disclosures